Bruton's Tyrosine Kinase is involved in innate and adaptive immunity

被引:0
|
作者
Brunner, C [1 ]
Müller, B [1 ]
Wirth, T [1 ]
机构
[1] Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany
关键词
Btk; toll-like receptors; B cells; myeloid cells;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signalling. Gene targeting experiments revealed that Btk is important for B cell development and function. However, Btk is not only expressed in B cells, but also in most other haematopoietic lineages except for T cells and plasma cells. Recently we found that Btk is involved in Toll-like receptor signalling. Toll-like receptors play an important role in innate immunity. They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens. Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.
引用
收藏
页码:945 / 955
页数:11
相关论文
共 50 条
  • [41] Bruton's tyrosine kinase (Btk) associates with protein kinase C μ
    Johannes, FJ
    Hausser, A
    Storz, P
    Truckenmüller, L
    Link, G
    Kawakami, T
    Pfizenmaier, K
    FEBS LETTERS, 1999, 461 (1-2) : 68 - 72
  • [42] Bruton's Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
    Bonami, Rachel H.
    Thurman, Christina E.
    Verma, Sonam
    Westlake, Camille S.
    Nyhoff, Lindsay E.
    Barron, Bridgette B.
    Reboldi, Andrea
    Kendall, Peggy L.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [43] Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity
    Liu, Zhida
    Han, Chuanhui
    Dong, Chunbo
    Shen, Aijun
    Hsu, Eric
    Ren, Zhenhua
    Lu, Changzheng
    Liu, Longchao
    Zhang, Anli
    Timmerman, Casey
    Pu, Yang
    Wang, Yang
    Chen, Mingyi
    Qiao, Jian
    Fu, Yang-Xin
    SCIENCE IMMUNOLOGY, 2019, 4 (38)
  • [44] Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
    Pan, Zhengying
    Scheerens, Heleen
    Li, Shyr-Jiann
    Schultz, Brian E.
    Sprengeler, Paul A.
    Burrill, L. Chuck
    Mendonca, Rohan V.
    Sweeney, Michael D.
    Scott, Keana C. K.
    Grothaus, Paul G.
    Jeffery, Douglas A.
    Spoerke, Jill M.
    Honigberg, Lee A.
    Young, Peter R.
    Dalrymple, Stacie A.
    Palmer, James T.
    CHEMMEDCHEM, 2007, 2 (01) : 58 - 61
  • [45] Mutations in Bruton's Tyrosine Kinase Impair IgA Responses
    Mitsuiki, N.
    Yang, X.
    Bartol, S.
    Kosaka, Y.
    Takada, H.
    Imai, K.
    Kanegane, H.
    Mizutani, S.
    van der Burg, M.
    van Zelm, M.
    Ohara, O.
    Morio, T.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S430 - S431
  • [46] The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstrom's Macroglobulinemia
    Khan, Abdullah Mohammad
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (05):
  • [47] Expression of Bruton's tyrosine kinase in multiple myeloma.
    Zhou, Guangbiao
    Liu, Ying
    Zhang, Bo
    Meng, Fanyi
    Liu, Xiaoli
    BLOOD, 2007, 110 (11) : 261B - 261B
  • [48] Targeted selective degradation of Bruton's tyrosine kinase by PROTACs
    Liu, Shaodong
    Da, Yang
    Wang, Feng
    Yan, Renjie
    Shu, Yongzhi
    Lin, Pei
    Lin, Jun
    MEDICINAL CHEMISTRY RESEARCH, 2020, 29 (04) : 802 - 808
  • [49] Targeting Bruton's tyrosine kinase in B cell malignancies
    Rudi W. Hendriks
    Saravanan Yuvaraj
    Laurens P. Kil
    Nature Reviews Cancer, 2014, 14 : 219 - 232
  • [50] Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis
    Shulga, Olga
    Chabanova, Anna
    Kotsiuba, Oleksandra
    POSTEPY PSYCHIATRII I NEUROLOGII, 2023, 32 (01): : 23 - 30